trending Market Intelligence /marketintelligence/en/news-insights/trending/vwVbmacmJ3G84FRpUFkH2A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sanofi kicks off tender offer to acquire Synthorx for $2.5B

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sanofi kicks off tender offer to acquire Synthorx for $2.5B

Sanofi began its tender offer to acquire all common shares of immuno-oncology company Synthorx Inc. at $68 each.

The deal is valued at $2.5 billion, and the acquisition is expected to boost French drugmaker Sanofi's oncology and immuno-oncology pipeline with Synthorx's lead asset, THOR-707, which is being studied as a potential treatment for multiple solid tumor types.

Sanofi's offer is expected to expire Jan. 22, 2020.

Morgan Stanley & Co. is acting as financial adviser to Sanofi, with Weil Gotshal & Manges LLP serving as legal counsel. Centerview Partners LLC is the exclusive financial adviser to Synthorx, while Cooley LLP is acting as legal counsel.